Difference between revisions of "Afuresertib (GSK-2110183)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 15: Line 15:
 
[[Category:AKT1 inhibitors]]
 
[[Category:AKT1 inhibitors]]
  
[[Category:Multiple myeloma medications]]
+
[[Category:Multiple myeloma medications (investigational)]]
  
 
[[Category:Investigational drugs]]
 
[[Category:Investigational drugs]]

Revision as of 17:20, 26 April 2022

Mechanism of action

From the NCI Drug Dictionary: An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis.

Preliminary data

Multiple myeloma

  1. Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. link to original article PubMed

Also known as

  • Code name: GSK2110183